Press releases
- Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
- Quest Diagnostics Declares Quarterly Cash Dividend
- Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
- Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
- Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 136.51 |
---|---|
High | 136.51 |
Low | 136.51 |
Bid | 137.98 |
Offer | 138.03 |
Previous close | 136.51 |
Average volume | -- |
---|---|
Shares outstanding | 111.09m |
Free float | 110.61m |
P/E (TTM) | 19.09 |
Market cap | 15.76bn USD |
EPS (TTM) | 7.43 USD |
Annual div (ADY) | 2.74 CHF |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Next div ex-date | Jul 08 2024 |
Next div pay-date | Jul 22 2024 |
Data delayed at least 15 minutes, as of Aug 30 2021.
More ▼